Respiratory Science最新文献_第5页

Endobronchial Tuberculosis: Diagnosis and Treatment Approach 支气管内结核的诊断和治疗方法

Respiratory Science Pub Date : 2021-10-15 DOI: 10.36497/RESPIRSCI.V2I1.24

Y. Arliny, Diennisa Mursalin

引用次数: 0

Cholesterol Level in Covid-19 Patients Related to Severity and Mortality: A Case Series and Literature Review Covid-19患者的胆固醇水平与严重程度和死亡率相关:病例系列和文献综述

Respiratory Science Pub Date : 2021-10-15 DOI: 10.36497/RESPIRSCI.V2I1.28

Anggarda Kristianti Utomo, H. Haryati

{"title":"Cholesterol Level in Covid-19 Patients Related to Severity and Mortality: A Case Series and Literature Review","authors":"Anggarda Kristianti Utomo, H. Haryati","doi":"10.36497/RESPIRSCI.V2I1.28","DOIUrl":"https://doi.org/10.36497/RESPIRSCI.V2I1.28","url":null,"abstract":"Coronavirus Disease 2019 (COVID-19) is a communicable disease caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). December 2019 in Wuhan, China, is the time and place where the first pneumonia case which SARS-CoV-2 causes was found, and WHO designated COVID-19 as a pandemic by March 2020. There are reported cases of dyslipidemia associated with SARS patients, albeit rare. Several case reports showed lower cholesterol levels compared to healthy subjects. Therefore, some argued that dyslipidemia could occur in COVID-19. Several studies have revealed that hypolipidemia is positively correlated with the severity of COVID-19. In Ulin Regional Hospital Banjarmasin, several cases found higher cholesterol levels in asymptomatic and mild-moderate COVID—19 survivor compared to patients with severe/critical COVID-19and non-survivor. Two patients in the non-survivor group showed a significant decrease in cholesterol level compared to baseline, and five patients had <150 mg/dL cholesterol level during the examination. Four mild-moderate COVID-19 survivors had cholesterol levels that were greater than 150 mg/dL at the first examination and did not decrease during the evaluation. Cholesterol is thought to play an important role in the pathological development of COVID-19, and it is associated with severity and mortality, which requires further studies.","PeriodicalId":377868,"journal":{"name":"Respiratory Science","volume":"84 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116673496","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Chest Wall Syndrome 胸壁综合征

Respiratory Science Pub Date : 2021-10-15 DOI: 10.36497/RESPIRSCI.V2I1.34

I. M. Soetartio, A. Susanto, D. Soehardiman, Budhi Antariksa

引用次数: 1

Role of Incentive Spirometry On Exercise Capacity, Breathing Symptoms, Depression Rate, and Quality of Life in NSCLC Patients with Chemotherapy 激励性肺活量测定在非小细胞肺癌化疗患者运动能力、呼吸症状、抑郁率和生活质量中的作用

Respiratory Science Pub Date : 2021-10-15 DOI: 10.36497/RESPIRSCI.V2I1.33

Dian Apriliana, Suradi, A. Setijadi

{"title":"Role of Incentive Spirometry On Exercise Capacity, Breathing Symptoms, Depression Rate, and Quality of Life in NSCLC Patients with Chemotherapy","authors":"Dian Apriliana, Suradi, A. Setijadi","doi":"10.36497/RESPIRSCI.V2I1.33","DOIUrl":"https://doi.org/10.36497/RESPIRSCI.V2I1.33","url":null,"abstract":"Backgrounds: Pulmonary rehabilitation is a non-pharmacological therapy that improves breathing capacity in lung cancer patients. This study aimed to determine the effects of incentive spirometry (IS) on exercise capacity, breathing symptoms, depression rates, and quality of life in lung cancer patients with chemotherapy.\u0000Method: This quasi-experimental study was done through purposive sampling of 32 lung cancer patients who underwent chemotherapy for at least three cycles at Dr. Moewardi General Regional Hospital, Surakarta, from December 2019 to February 2020.Data on 6 minutes walking test (6-MWT) to evaluate exercise capacity, breathing symptoms (BORG scale), level of depression (HRSD questionnaire), and quality of life (SGRQ questionnaire) .\u0000Results: Experimental group showed higher value of 6-MWT (72.75±152.50 meters vs. 31.81 ± 27.67, P=0.010), a decrease in the BORG scale (-1.78±1.72 vs. -0.38±1.67, P=0.013), Hamilton's score improvement (-2.25±5.12 vs. -4.25±5.34, P=0.075), and improvement in the SGRQ value (-10.77±9.82 vs. -0.08±11.16, P=0.752) compared to those of control group.","PeriodicalId":377868,"journal":{"name":"Respiratory Science","volume":"9 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"128448457","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

CT Guided TTNA and Core Biopsy in Suspected Lung Cancer, Review of Cases in Adam Malik General Hospital, Medan CT引导下TTNA及核心活检在疑似肺癌诊断中的应用——附棉兰Adam Malik总医院病例分析

Respiratory Science Pub Date : 2021-10-15 DOI: 10.36497/RESPIRSCI.V2I1.27

Hadi Suhendra, Fajrinur Syarani, S. Bihar, P. Eyanoer

引用次数: 0

Role of Mesenchymal Stem Cells In Chronic Obstructive Lung Disease 间充质干细胞在慢性阻塞性肺疾病中的作用

Respiratory Science Pub Date : 2021-06-23 DOI: 10.36497/respirsci.v1i3.26

Fatmi Andari, Triya Damayanti

引用次数: 1

Remdesivir for COVID-19 in Indonesia : A Case Series 瑞德西韦在印度尼西亚治疗COVID-19:病例系列

Respiratory Science Pub Date : 2021-06-23 DOI: 10.36497/RESPIRSCI.V1I3.22

Gembong Satria Mahardhika, H. Zain, Theodore Dharma Tedjamartrono, Ef Ismail

{"title":"Remdesivir for COVID-19 in Indonesia : A Case Series","authors":"Gembong Satria Mahardhika, H. Zain, Theodore Dharma Tedjamartrono, Ef Ismail","doi":"10.36497/RESPIRSCI.V1I3.22","DOIUrl":"https://doi.org/10.36497/RESPIRSCI.V1I3.22","url":null,"abstract":"To date, COVID-19 still gives rise to a high mortality rate in Indonesia. The definitive therapy has yet to be found. However, some medications are said to be potential in subduing the infection, e.g. remdesivir. United States, Japan, and some countries in Europe had use remdesivir against severe COVID-19 infection. In Indonesia, no study has shown to discuss remdesivir therapy for severe COVID-19. This case series shows the first five remdesivir usages in severe COVID-19 patients in RSDC Wisma Atlet Kemayoran, Jakarta. In this retrospective case series, we include the first five severe COVID-19 patients that got remdesivir plus standard therapy in Rumah Sakit Darurat COVID-19 Wisma Atlet Kemayoran, Jakarta in October 2020. Five patients who got remdesivir in this case series experienced clinical and laboratory improvement. The ventilation and oxygenation status, as well as PF ratio and the neutrophils-lymphocytes ratio (NLR), got better. The possible side effect of remdesivir usage, renal function impairment, was not seen in these patients. At last, the five patients were discharged home with negative swab results, three until seven days after remdesivir therapy finished. Remdesivir therapy for COVID-19 in this case series is associated with a good outcome. Compassionate use of remdesivir should be considered in severe COVID-19. However, a bigger sample of randomized control trial needs to be done to show the effectiveness of remdesivir against COVID-19.","PeriodicalId":377868,"journal":{"name":"Respiratory Science","volume":"72 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116178247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Programmed Death Ligand 1 (PD-L1) Expression in Lung Adenocarcinoma Patients 程序性死亡配体1 (PD-L1)在肺腺癌患者中的表达

Respiratory Science Pub Date : 2021-06-23 DOI: 10.36497/RESPIRSCI.V1I3.16

R. Hidayat, N. Soeroso, E. Syahruddin, Dian Cahyadi, Setiaputra Setiaputra

{"title":"Programmed Death Ligand 1 (PD-L1) Expression in Lung Adenocarcinoma Patients","authors":"R. Hidayat, N. Soeroso, E. Syahruddin, Dian Cahyadi, Setiaputra Setiaputra","doi":"10.36497/RESPIRSCI.V1I3.16","DOIUrl":"https://doi.org/10.36497/RESPIRSCI.V1I3.16","url":null,"abstract":"Background: Programmed Death Ligand 1 (PD-L1) is a protein found in tumor cells that could inactivate T-cells. This research was done to identify the characteristics of lung adenocarcinoma patients to PD-L1 expression in Medan. \u0000Method: Descriptive research with a cross-sectional design was used and the study was done for 12 months (January – December 2018). Sample’s collection was done at RSUP (Central Public Hospital) H. Adam Malik and the samples diagnosed with lung adenocarcinoma based on histopathological subtyping were sent to the laboratory of Dharmais Jakarta Hospital where the Ventana 22C3 Immunohistochemistry Staining was done.\u0000Results: Staining was done in 52 samples at Dharmais Jakarta Hospital and only 35 samples were deemed acceptable. In this study, participants’ ages ranged from 40 to 60 years, where the majority were male patients, 31 (88.6%) and 33 patients (82.5%) were at an advanced stage (III and IV).\u0000Conclusion: The study found that the PD-L1 expression was mostly observed in male at the age range of 40 – 60 years and stage IV lung adenocarcinoma patients with Tumour Proportion Score (TPS) of 1 – 49%.","PeriodicalId":377868,"journal":{"name":"Respiratory Science","volume":"13 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"123604753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Accuracy Between CURB-65 Score and PSI in Determining The Prognosis of Community-Acquired Pneumonia Patients at H. Adam Malik General Hospital, Medan 棉兰亚当马利克总医院CURB-65评分与PSI在判断社区获得性肺炎患者预后中的准确性

Respiratory Science Pub Date : 2021-06-23 DOI: 10.36497/respirsci.v1i3.25

Fransisco Sentosa Pakpahan, S. Bihar, Fajrinur Syarani, P. Eyanoer

{"title":"Accuracy Between CURB-65 Score and PSI in Determining The Prognosis of Community-Acquired Pneumonia Patients at H. Adam Malik General Hospital, Medan","authors":"Fransisco Sentosa Pakpahan, S. Bihar, Fajrinur Syarani, P. Eyanoer","doi":"10.36497/respirsci.v1i3.25","DOIUrl":"https://doi.org/10.36497/respirsci.v1i3.25","url":null,"abstract":"Background: Community-Acquired Pneumonia (CAP) is an important problem associated with morbidity and mortality. An accurate initial assessment is required before starting management of a CAP patient to determine the prognosis of the patient as early as possible. The CURB-65 score and PSI (Pneumonia Severity Index) are initial assessment scores that can be used. This study aimed to compare the accuracy between the CURB-65 score and the PSI in determining the prognosis in CAP patients at H. Adam Malik General Hospital Medan.\u0000Method: A descriptive study was conducted on 76 patients diagnosed with CAP. Each patient was assessed for their CURB-65 score, PSI class and mortality within 30 days of admission. Data were collected through patient medical records diagnosed CAP in 2018 and performed statistical analysis using 2x2 tables.\u0000Results: The CURB-65 ≥3 score showed accuracy (71.0%), sensitivity (53.8%), and specificity (89,2%). The CURB-65 ≥ 2 score showed accuracy (75.0%), sensitivity (82.1%), and specificity (67.6%). Meanwhile, the Class IV-V PSI showed accuracy (77.6%), sensitivity (87.2%) and specificity (67.6%).\u0000Conclusion: The accuracy of the PSI is higher when compared to the CURB-65 score in determining the prognosis of CAP patients at H. Adam Malik General Hospital Medan. Although PSI is more accurate, CURB-65 is simpler, easier and less expensive to use","PeriodicalId":377868,"journal":{"name":"Respiratory Science","volume":"5 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131839454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

New GOLD COPD Guideline 2019: How We Deal with It? (Inhaled Corticosteroid Use and Blood Eosinophil Count) 新的GOLD COPD指南2019:我们如何应对?(吸入皮质类固醇使用及血液嗜酸性粒细胞计数)

Respiratory Science Pub Date : 2021-02-27 DOI: 10.36497/RESPIRSCI.V1I2.13

Ari Julian Saputra, K. Widyastuti, Y. Sutanto

{"title":"New GOLD COPD Guideline 2019: How We Deal with It? (Inhaled Corticosteroid Use and Blood Eosinophil Count)","authors":"Ari Julian Saputra, K. Widyastuti, Y. Sutanto","doi":"10.36497/RESPIRSCI.V1I2.13","DOIUrl":"https://doi.org/10.36497/RESPIRSCI.V1I2.13","url":null,"abstract":"Background: Blood eosinophils may predict response to inhaled corticosteroids (ICS) in chronic obstructive pulmonary disease (COPD), where ICS is recommended in patients at high risk of exacerbations by the Global Initiative for COPD (GOLD) strategy. It can help clinicians to estimate the likelihood of beneficial preventive responses to the addition ICS to regular bronchodilator treatment, and thus can be used as a biomarker in conjunction with clinical assessment when making decisions regarding ICS use. This study aims to compare therapeutic data with blood eosinophil count in COPD patients. \u0000Methods: Data were collected from consecutive COPD outpatients in Bukit Asam Medika Hospital starting from March 1st, 2019 until June 30th, 2019 and dr. H. Mohamad Rabain Hospital starting from Oct 1st, 2019 until Dec 27th, 2019. We collected demographics, anthropometrics, smoking history, therapy, dynamic lung volumes, the Medical Research Council scale (MRC), CAT score, and blood eosinophil count. \u0000Results: From 57 data collected, 24 (42,1%) patients were having blood eosinophil count ≥300. Patients who have more exacerbation in COPD Group C were 33,3% and 63,2% in COPD Group D. The proportions of ICS-treated COPD Group D patients and blood eosinophil count of <300 and ≥300 was 63,9% and 36,1%, respectively. \u0000Conclusion: This study may provide information and characteristic of COPD patient in Indonesia rural area and showed who may have benefit to ICS therapy based on recommendation GOLD COPD 2019. Blood eosinophils counts is a low-cost biomarker and may help clinicians to made decision therapy.","PeriodicalId":377868,"journal":{"name":"Respiratory Science","volume":"25 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134475813","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0